Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a significant side effect of
chemotherapy. These new potent therapies may not only affect the survival of cancer cells, but have the potential to adversely
impact normal cardiac and vascular function. Unraveling the mechanisms by which these therapies affect the heart
and vasculature is crucial for improving drug design and finding alternative therapies to protect patients predisposed to
cardiovascular disease. In this review, we summarize the classification and side effects of currently approved molecularly
Keywords: Cardiac toxicity, chemotherapy, cardiomyopathy, tyrosine kinases, proteasome inhibitors.
Rights & PermissionsPrintExport